Speakers

Adelaide University
Australia

READ BIO

Professor Stuart Brierley is Director of the Visceral Pain Research Group, Director of the Hopwood Centre for Neurobiology, and Co-leader of the Lifelong Health theme at the South Australian Health and Medical Research Institute (SAHMRI). He is also an Affiliate of the School of Biomedicine, Faculty of Health and Medical Sciences, Adelaide University.

He is an international expert in the ‘gut-brain axis’ and chronic visceral pain mechanisms. He is an NHMRC Investigator Leadership recipient and received a NHMRC Research Excellence Award in 2016. His research is funded by the NHMRC, ARC, NIH and industry.

University of Queensland
Australia

READ BIO

James Cook University
Australia

READ BIO

Prof Daly’s research is focused on developing peptide-based lead compounds for drug design applications. Most of this work is based on proteins derived or engineered from parasites or from venomous animals found in the tropics. Major outcomes from her research include: (a) Development of an orally active peptide with potential in treating inflammatory bowel disease; (b) Development of a highly potent wound-healing agent based on a liver fluke protein. This wound healing agent is being further developed through a recently established consortium, UHEAL, which brings together clinicians and researchers involved in all aspects of wound healing; (c) Determination of the three-dimensional structures of more than 100 peptides; these studies have provided the basis for the discovery of new peptide families, insight into structure/function relationships, and the design of novel peptides with therapeutic potential.

Prof Daly will contribute to the Centre through collaborations involving development of drug leads for inflammatory diseases and discovery of new peptides from tropical flora and fauna.

Stanford University
United States

READ BIO

Du Bois is the Department Chair and Henry Dreyfus Professor of Chemistry at Stanford University and, by courtesy, Professor of Chemical and Systems Biology. He is a distinguished teacher and holds the title of Bass University Fellow in Undergraduate Education. In 2010, he cofounded SiteOne Therapeutics, Inc, a pharmaceutical start-up aimed at developing sodium channel subtype-selective inhibitors as analgesic medicines. This company was recently acquired by Eli Lilly.

Du Bois’ research interests span chemical design and synthesis, physical organic chemistry, biochemistry, and electrophysiology. He and his team are investigating the molecular physiology of voltage gated ion channels, namely sodium (NaV) and chloride (ClC), and the role specific channel subtypes play in pain perception and epilepsy. His lab uses natural toxins—saxitoxin, gonyautoxin, batrachotoxin, antillatoxin, to name a few—as well as designed molecules (AK-42) as lead compounds to develop high precision molecular tools for modulating individual channel isoforms, live-cell imaging, and proteomics studies.

University of Queensland
Australia

READ BIO

Venoms play a range of adaptive roles in the animal kingdom from predation to defense to competitor deterrence. Remarkably, despite their biological importance and uniqueness, the evolution of venom systems is poorly understood. New insights into the evolution of venom systems and the importance of the associated toxins cannot be advanced without recognition of the true biochemical, ecological, morphological and pharmacological diversity of venoms and associated venom systems. A major limitation has been the very narrow taxonomical range studied. Entire groups of venomous animals remain virtually unstudied. My research is inherently interdisciplinary, integrating ecological, evolutionary, and functional genomics approaches in order to understand the evolution of venom systems. Studies range from discovering the shock-inducing hypotensive and anticoagulant venom of the iconic Komodo Dragon through to exploring the unique temperature specific adaptations of Antarctic octopus venoms.

National University of Singapore
Singapore

READ BIO

Manjunatha Kini bioR. Manjunatha Kini is a researcher affiliated with the National University of Singapore. Their work primarily spans the fields of Biochemistry, Genetics, and Molecular Biology, with considerable contributions to Medicine as well. Their research encompasses a broad range of subfields including Molecular Biology, Genetics, Public Health, Environmental and Occupational Health, Infectious Diseases, and Insect Science.

Major research topics covered by Kini include venomous animal envenomation and studies, mosquito-borne diseases and control, viral infections and vectors, ion channel regulation and function, nicotinic acetylcholine receptors study, insect symbiosis and bacterial influences, and biochemical and structural characterization.

Macquarie University
Australia

Read Bio

A/Prof Maciej Maselko leads a research group in Applied BioScience at Macquarie University and is the CEO of EntoZyme. His work focuses on using animal synthetic biology to address environmental and human health challenges. These include novel genetic biocontrol tools for invasive species, animals engineered for bioremediation, and transgenic insects for sustainable waste management and biomanufacturing. He earned his PhD in Molecular Biology from Oregon State University followed by a USDA-NIFA fellowship and postdoctoral work at the University of Minnesota.

Maxion Therapeutics
United Kingdom

READ BIO

John McCafferty is a highly accomplished scientist and entrepreneur with a rich history of leadership in the biopharmaceutical industry. With a career spanning over two decades, he has made significant contributions to the fields of biochemistry, cancer biology, and therapeutic development. As the founder and CEO of Maxion Therapeutics, John has been at the forefront of innovative therapeutic solutions, leveraging his extensive knowledge and experience to drive advancements in treatment protocols as well as drug design. Known for his visionary approach, he has successfully secured partnerships and collaborations that have brought strategic direction to Maxion Therapeutics, ultimately benefiting patients worldwide.

Before his role at Maxion Therapeutics, John co-founded IONTAS, where he served as Chief Scientific Officer (CSO). During his tenure at IONTAS, he was instrumental in developing high-performance antibody therapies, utilizing his expertise in combinatorial antibody technologies. His innovative approach and dedication to advancing science and patient care have significantly bolstered the company’s reputation in the antibody-drug conjugate space.

University New South Wales
Australia

READ BIO

Associate Professor Kate Michie is Chief Scientist of the Structural Biology Facility at UNSW Sydney and an academic in the School of Biotechnology and Biomolecular Sciences. She specialises in structural biology and biophysics, with a focus on integrating experimental approaches with emerging computational methods.

Kate trained in protein chemistry and biophysics at the University of Sydney (BSc (Hons), PhD), before undertaking Marie Curie and L’Oréal–UNESCO fellowships at the MRC Laboratory of Molecular Biology, Cambridge, where she transitioned into structural biology. Her work now centres on embedding deep learning–based structure prediction into routine structural biology workflows, alongside cryo-EM, crystallography and biophysical characterisation.

Her research focuses on protein-protein interaction prediction, complex modelling, and the application of protein design approaches, including binder design. She is particularly interested in the capabilities and limitations of current predictive models, and how they can be applied critically to interpret molecular interactions, guide experimental design, and avoid over-interpretation in the analysis of protein interfaces.

University of California
United States 

READ BIO

Dr. Samantha Nixon’s research centers on structural biology and recombinant expression, with a specialized focus on harnessing natural chemistries like spider venoms to create next-generation drugs for neglected tropical diseases and livestock parasites

Seattle Children's Research Institute
United States

READ BIO

My scientific and medical career has been devoted primarily to discovering and advancing new therapies for pediatric brain tumor patients. The children in my clinical practice over the past 27 years have motivated our lab’s translational research, which led to 12 human clinical trials. I recently led a Phase 3 Children’s Oncology Group trial in more than 150 institutions that improved five-year overall survival for high-risk Group 3 medulloblastoma patients from 64% to 83%. Our lab invented Tumor Paint, a molecular imaging agent designed to guide surgeons as they remove tumors with minimal damage to adjacent normal tissue.. Over the past nine years, our lab has evolved into a protein therapeutics lab with a sharp focus on bispecific and multispecific therapeutics.

University of Vienna
Austria

READ BIO

University of Debrecen
Hungary

READ BIO

Dr. Gyorgy Panyi is a professor and head of the Department of Biophysics and Cell Biology at the University of Debrecen, Faculty of Medicine, Hungary. Dr. Panyi has graduated as a Medical Doctor in 1991, has earned his PhD in 1996 in Biophysics, both degrees were awarded at the University Medical School of Debrecen, Hungary. Part of his research training toward the PhD degree was completed at the University of Pennsylvania, Department of Physiology where he spent 2 years and worked on the molecular mechanism of slow inactivation of K+ channels, and between 2005-06, to study the coupling of activation and inactivation gates in voltage-gated K+ channels.

Dr. Panyi built his career and established his own lab at the University of Debrecen. His research focuses on the molecular pharmacology of voltage-gated K+ channels, more precisely, he isolated and characterized several high affinity Kv1.3 inhibitors isolated from scorpions. He has extended his research in molecular pharmacology of Kv1.3 and focusing primarily on the principles determining the selectivity of the toxins between Kv1.2 and Kv1.3. More recently, he started to work on modified toxins having for example fluorescence protein conjugate and set out experiments to describe the interaction of peptide toxins with heteromeric Kv channels.

Parallel to the toxin research he demonstrated the recruitment of Kv1.3 channels into the immunological synapse, which opened a completely new aspect of the regulation of the immune system by ion channels.

Dr. Panyi published ~150 papers in international peer reviewed journals and mentored 13 graduated PhD students. He built an extensive international collaboration network with scientist from Australia, USA and Israel.

Dr. Panyi’s most significant honor is the European Biophysical Societies’ Association prize (EBSA prize, 2005) “for his innovative contribution to the biological and pharmacological aspects of K+ channels in T lymphocytes”

University of Utah
United States

READ BIO

Associate Professor Helena Safavi-Hemami, PhD, is a researcher at the University of Utah specializing in the biochemistry of marine venoms, particularly cone snails, to develop novel therapeutics for pain, epilepsy, and diabetes. She leads a lab investigating peptide-based toxins that mimic human hormones.

University of Queensland
Australia

READ BIO

University of Queensland
Australia

READ BIO

Founder–executive and medicinal chemist with more than 30 years of experience building biotechnology companies and translating platform science into clinical assets and marketed drugs. I have contributed to the discovery of multiple drugs, including Icotyde and Relenza, with Rusfertide currently under final NDA review. I have founded six companies, Cytokine Mimetics Ltd, Protagonist Pty Ltd, Pharmamonde, Protagonist Therapeutics Inc, Vast Bioscience, and Infensa Bioscience, that have collectively advanced seven compounds through 31 clinical trials, including 10 Phase 3 programs. I founded Protagonist Therapeutics and helped grow it from an Australian startup into a transcontinental public biotech company with operations in Brisbane and the San Francisco Bay Area. I am currently the co‑founder and CEO of Infensa Bioscience, translating University of Queensland venom‑based peptide discoveries to clinical candidates.

Cawthron Institute
New Zealand

READ BIO

Johan joined Cawthron in 2019 as the Science Leader of Algal Research and Bioactives and currently holds the position as Science Impact Manager at the institute. Johan’s main research areas of interest are marine natural products, marine biotechnology, antifouling, medicinal chemistry, biomaterials and peptide chemistry. At Cawthron, Johan leads Cawthron’s development of a New Zealand algae sector by exploring collaborative R&D programmes to generate algal based products, novel bioactives for commercial applications, as well as analytical toxin standards.

Johan’s research background includes a wealth of international experience. After completing his PhD in 2003, Johan spent 10 years in Norway working on marine bioprospecting and searching for novel bioactive natural products in Arctic marine organisms and algae. In addition, he spent 15 years leading the development of bioactive peptides inspired by natural compounds. Previous roles include Associate Professor (docent) in Biomaterials Chemistry at the Linnaeus University (Sweden), and Research Manager of Chemistry and Materials at RISE Research Institute of Sweden.

In addition to a passion for marine life, he brings a chemical viewpoint and a commercial perspective to the algal research at the Cawthron Institute. Despite not being in the lab too much these days Johan remains a prolific writer and has co-authored 77 research papers and more than 30 miscellaneous and popular science articles.

University of Oslo
Norway

READ BIO

Eivind A. B. Undheim is a research group leader in the Centre for Ecological and Evolutionary Synthesis at the University of Oslo, Norway, whose research focuses on the mechanisms and processes that underlie evolutionary innovation and the emergence of novel traits. He is particularly interested in the biology and evolution of venoms, which are fascinating and key adaptive traits for a wide range of organisms that provide outstanding opportunities for studying evolutionary innovation and novelty at levels that range from morphology to molecules. Undheim also has a keen interest in how understanding venom protein and peptide evolution can guide the development of novel analytical and molecular tools as well as the discovery of new therapeutic and agrochemical leads.

Russian Academy of Sciences
Russia

READ BIO

Dr. Alexander Vassilevski is a Principal Investigator and senior scientist at the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences (IBCh RAS) in Moscow, where he leads research at the interface of venom peptide chemistry, ion channel pharmacology, and neurobiology.

His laboratory focuses on discovering and characterizing bioactive peptides from animal venoms, particularly spider venoms, and developing these molecules as tools for neuroscience research and as leads for therapeutic development. Key areas of interest include the modulation of ion channels and neuroreceptors, the creation of subtype-selective ligands for potassium and sodium channels, and the design of fluorescent probes to map channel distribution in neural tissues.

Dr. Vassilevski’s work spans structural and functional studies of venom peptides, with applications in pain research, neuropharmacology, and drug discovery. He has co-authored numerous publications on venom-derived peptides that selectively target receptors and channels of biomedical interest.

University of Queensland
Australia

READ BIO

Prof Irina Vetter is Head of the Sensory Neuropharmacology Group and an NHMRC Investigator at The University of Queensland. She obtained her PhD in 2007 from the UQ School of Pharmacy and subsequently held NHMRC-funded postdoctoral fellowships at the Queensland Brain Institute and the Institute for Molecular Bioscience, where she developed expertise in ion channel pharmacology and venom peptide bioactivity.

Her research focuses on the discovery and mechanistic characterisation of bioactive molecules from animal venoms, with a particular emphasis on venom-derived modulators of ion channels involved in pain signalling. Prof Vetter leads multidisciplinary programs integrating toxinology, neuropharmacology and translational drug discovery to identify novel therapeutic leads from venom peptides. She is Lead Investigator on the NHMRC-funded Deadly Venoms program, which aims to harness the pharmacological diversity of venom peptides to develop new treatments for pain and other disorders.

Prof Vetter has extensive experience in toxinology, sensory neuroscience, and high-throughput functional screening, and her work has contributed to the identification of new molecular targets and lead compounds for analgesic development. She is the recipient of the International Association for the Study of Pain Patrick Wall Young Investigator Award (2018). Her current research centres on understanding peripheral pain mechanisms and leveraging venom-derived ion channel modulators as next-generation therapeutics.

Monash University
Australia

READ BIO

Denise Wootten is a Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University, a Senior Research Fellow of the National Health and Medical Research Council of Australia, and the Monash node leader for the ARC Centre for Cryo-EM of Membrane Proteins (CCeMMP). Prof. Wootten is an international expert in the study of G protein-coupled receptors (GPCRs), particularly the class B1 GPCR subfamily. Her research is directed towards understanding drug action at GPCRs, in particular modes of GPCR activation, signalling and regulation, biased agonism, allosteric modulation and the interaction of receptors with regulatory accessory proteins, and the application of cryo-EM to GPCR structure elucidation. Her research incorporates structural biology (cryo-EM), molecular, cellular and analytical pharmacology, computational biology, and preclinical mouse models of metabolic disease. She has published >100 peer reviewed research publications, and is an associate member of the Faculty of 1000, serves on the editorial board of the British Journal of Pharmacology and is a scientific advisor for Septerna Inc.

University of China
China

READ BIO

Prof. Rilei Yu's research focuses on the intelligent discovery and structural optimization of marine peptide drug leads (especially from Cone snail venom). He has led over five projects including the National Natural Science Foundation of China (NSFC) Excellent Youth Project, Key Projects of the Joint Fund, and the National Key R&D Program. He has published more than 110 SCI papers, with over 30 as first or corresponding author in the last five years in journals such as Molecular Cell, Nature Communications, Acta Pharmaceutica Sinica B, Pharmacology & Therapeutics, Briefings in Bioinformatics, and the Journal of Medicinal Chemistry. His innovative work has resulted in 8 national invention patents, 2 PCT applications, 5 authorized patents, one software copyright. He has received numerous accolades including the Marine Science and Technology Innovation Award (2025, 2023), the Qingdao Youth Science and Technology Award (2022).

University of Queensland
Australia

READ BIO

My research interests are centred around the structure and function of venom and silk polypeptides produced by arthropods, and their use in biotechnology and medicine. I am a Postdoctoral Fellow in the King laboratory in the Institute for Molecular Bioscience, the University of Queensland, Australia. Currently, I am investigating the composition, function and evolution of neglected insect venoms produced by assassin bugs (Hemiptera: Reduviidae), robber flies (Diptera: Asilidae) and nettle caterpillars (Lepidoptera: Limacodidae).